Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Completed Phase 2 Interventional Results available

Randomized Double Cord Blood Transplant Study

NCT00067002
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
Interventions
Expanded allogeneic cord blood (CB), One Unmanipulated and One Expanded Cord Blood Unit, Rituxan, Melphalan, Thiotepa, Fludarabine, Cyclophosphamide, Mesna, Total body irradiation (TBI)
Procedure · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Month to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 23, 2026, 2:35 PM EDT
Not yet recruiting Phase 2 Interventional

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

NCT07886905
View directory record Official record
Conditions
Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
Interventions
Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos
Drug · Biological · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

NCT06414356
View directory record Official record
Conditions
Neuropathic Pain, PTSD
Interventions
Ketamine, Magnesium sulfate, Ketamine + Magnesium sulfate
Drug
Lead sponsor
Margaux M. Salas, PhD
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Active, not recruiting Phase 1 Interventional

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

NCT00840853
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
Interventions
CD19CAR/virus specific T cells, Benadryl and Tylenol
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

NCT03901339
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease

NCT00567177
View directory record Official record
Conditions
Treatment of Dry Eye Disease
Interventions
Restasis, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
6400 Fannin Ste 1800, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2010 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Expectations in Subjects With Osteoarthritis

NCT02155257
View directory record Official record
Conditions
Osteoarthritis
Interventions
Modafinil, Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 1 Interventional

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

NCT05609994
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
PEPIDH1M vaccine + vorasidenib
Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Natural Supplements for Unipolar Depression

NCT00226356
View directory record Official record
Conditions
Unipolar Depression
Interventions
Supplements of L-methionine, betaine and folate
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

NCT01673737
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR260301, Vemurafenib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

NCT00983931
View directory record Official record
Conditions
Pharmacokinetics, Healthy
Interventions
Colchicine, Cyclosporine
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 23, 2026, 2:35 PM EDT
Terminated Not applicable Interventional

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

NCT05797805
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Tegavivint, Lenvatinib, Cabozantinib
Drug
Lead sponsor
Iterion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

NCT00615056
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab (avastin), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
61
States / cities
Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00003829
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, fludarabine phosphate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
17
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 4 Interventional

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

NCT04462523
View directory record Official record
Conditions
Vitreo-Retinal Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Patrick R. Oellers, MD
Network
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

NCT07222579
View directory record Official record
Conditions
CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Subcutaneous Blinatumomab
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

NCT00398086
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, Albumin-bound paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 23, 2026, 2:35 PM EDT